ABSTRACT The NMDA-receptor antagonist ketamine has proven efficient in reducing symptoms of suicidality, although the mechanisms explaining this effect have not been detailed in psychiatric

patients. Recent evidence points towards a low-grade inflammation in brains of suicide victims. Inflammation leads to production of quinolinic acid (QUIN) and kynurenic acid (KYNA), an

agonist and antagonist of the glutamatergic _N_-methyl-D-aspartate (NMDA) receptor, respectively. We here measured QUIN and KYNA in the cerebrospinal fluid (CSF) of 64 medication-free

suicide attempters and 36 controls, using gas chromatography mass spectrometry and high-performance liquid chromatography. We assessed the patients clinically using the Suicide Intent Scale

QUIN in patients who came for follow-up lumbar punctures within 6 months after the suicide attempt. In summary, we here present clinical evidence of increased QUIN in the CSF of suicide

attempters. An increased QUIN/KYNA quotient speaks in favor of an overall NMDA-receptor stimulation. The correlation between QUIN and the Suicide Intent Scale indicates that changes in

glutamatergic neurotransmission could be specifically linked to suicidality. Our findings have important implications for the detection and specific treatment of suicidal patients, and might

explain the observed remedial effects of ketamine. SIMILAR CONTENT BEING VIEWED BY OTHERS GLUTAMATERGIC BASIS OF ANTIPSYCHOTIC RESPONSE IN FIRST-EPISODE PSYCHOSIS: A DUAL VOXEL STUDY OF THE

ANTERIOR CINGULATE CORTEX Article 26 September 2023 ALTERED LEVELS OF INTERLEUKINS AND NEUROTROPHIC GROWTH FACTORS IN MOOD DISORDERS AND SUICIDALITY: AN ANALYSIS FROM PERIPHERY TO CENTRAL

NERVOUS SYSTEM Article Open access 02 June 2021 SEX- AND SUICIDE-SPECIFIC ALTERATIONS IN THE KYNURENINE PATHWAY IN THE ANTERIOR CINGULATE CORTEX IN MAJOR DEPRESSION Article Open access 21

September 2023 INTRODUCTION Attempted suicide is associated with significant patient suffering, vast societal costs and an increased risk for completed suicide (Bruffaerts et al, 2011;

Hawton and van Heeringen, 2009). Despite increased treatment of suicidal individuals over the past decade, the incidence rates of suicidal behavior have remained largely unaltered (Nock et

al, 2008). Although many patients contact a physician shortly before the attempt, health care is frequently unable to prevent both attempted and completed suicides. Consequently, improved

methods for detection of suicide risk and specific treatments for suicidal patients are both highly warranted (Da Cruz et al, 2011). The neurobiology of suicidality is poorly understood.

Biological factors that have previously been associated with suicidality include serotonin and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) as well as growth factors, such as

brain-derived neurotrophic factor (Sher, 2011). Certain studies have shown an association between low levels of CSF 5-HIAA and suicidal behavior independent of depression (Asberg and

Traskman, 1981). Reduced serotonergic neurotransmission and suicidal behavior might thus be linked, but after more than 30 years of research, the association remains unspecific (Ernst et al,

2009). Interestingly, production of serotonin might be compromised during states of inflammation due to a consumption of tryptophan, the substrate for serotonin production (Oxenkrug, 2010).

Recent studies provide accumulating evidence that brain immune activation may be involved in the pathogenesis of suicidality. A _post-mortem_ study shows brain microglia activation in

suicide victims (Steiner et al, 2008), and the cytokine IL-6 is increased in the cerebrospinal fluid (CSF) of suicide attempters (Lindqvist et al, 2009). In addition, some studies indicate

that inflammation is more pronounced in suicidal patients than in non-suicidal depressed patients (Janelidze et al, 2011; Steiner et al, 2008). In support of a causal relationship between

inflammation and psychiatric symptoms, several studies show that immunotherapy with cytokines in patients induces depressive symptoms approximately 1 month after the beginning of the

medication (Raison et al, 2009; Wichers et al, 2005). Several case reports also describe suicidal ideation in previously psychiatrically healthy individuals after treatment with

interferon-_β_ (Fragoso et al, 2010). Inflammatory stimuli, such as central nervous system (CNS) infections, induce the kynurenine pathway of tryptophan degradation (Figure 1) and greatly

increase CSF levels of kynurenine and its metabolites (Heyes et al, 1992). Pro-inflammatory cytokines, especially interferon−_γ_, are considered the major inducers of

indoleamine-2,3-dioxygenase (IDO-1), one of the enzymes regulating the first step of the kynurenine pathway (Guillemin, 2012). Metabolism further along this pathway produces several

neuroactive compounds, including quinolinic acid (QUIN) and kynurenic acid (KYNA), both of which affect glutamatergic neurotransmission. A potential pathogenetic mechanism underlying

suicidal behavior could thus be via activation of the kynurenine pathway and through increased synthesis of QUIN and/or KYNA. Blood kynurenine levels were recently found to be elevated in

suicide attempters, as compared not only with healthy controls but also with patients with depression who never attempted suicide (Sublette et al, 2011). QUIN is an _N_-methyl-D-aspartate

(NMDA)-receptor agonist, activating receptors containing the NR1+NR2A and the NR1+NR2B subunits (de Carvalho et al, 1996; Stone, 1993). By contrast, KYNA, besides blocking the cholinergic

_α_7 nicotinic receptor, antagonizes the glycine site of the NMDA-receptor (Hilmas et al, 2001; Stone, 1993). Interestingly, the NMDA-receptor antagonist ketamine was recently shown to

reduce suicidality in four small-scale clinical studies (DiazGranados et al, 2010b; Larkin and Beautrais, 2011; Price et al, 2009; Zarate et al, 2012). This finding may principally suggest

enhanced NMDA-receptor signaling as part of the pathophysiology of suicidal behavior, although ketamine also has other effects in the central nervous system (Duman and Aghajanian, 2012). We

hypothesize that QUIN, and the QUIN/KYNA quotient, is elevated in suicide attempters due to a low-grade CNS inflammation. This might lead to excessive NMDA-receptor signaling, tentatively

explaining the observed remedial effects of ketamine on suicidality. Here, CSF levels of QUIN and KYNA are measured in suicide attempters and healthy controls. Furthermore, we assess whether

the QUIN levels are related to the depressive symptoms, and to suicidal intent using the Suicide Intent Scale (Beck, 1974). We also analyze whether QUIN and KYNA correlate with CSF levels

of the cytokine IL-6, which we have previously reported elevated in the suicide attempters (Lindqvist et al, 2009). A subset of the patients returned to the clinic at a follow-up occasion

within 6 months of the suicide attempt and provided a new CSF sample. This enables us to determine whether QUIN and KYNA levels change longitudinally in the same patients, at a time-point

when the patients were not suicidal. MATERIALS AND METHODS PARTICIPANTS, QUIN CSF STUDY We enrolled 64 patients (30 male and 34 female individuals), between 1988 and 2001, following

admission to Lund University Hospital after a suicide attempt. Psychiatric diagnoses of the patients are displayed in Table 1. Mean age of the patients was 37 years (range 19–72). The

patients underwent a washout period when they did not receive any antipsychotic or anti-depressive medication (14.6±9 days, mean±s.d.). Anxiolytic and hypnotic medications, as well as

somatic medications, were allowed during the wash-out. All medications taken are specified in Supplementary Table 1. At the end of the washout, lumbar punctures and psychiatric evaluations

were carried out as below (section 2.2). Thirty-six (29 male and 7 female individuals) healthy controls were recruited via the Psychiatric Clinics at the University Hospitals in Lund and

Linkoping, Sweden, between 2003 and 2009. Mean age of the controls was 30 years (range 18–66). They did not suffer from any previous or ongoing psychiatric condition or substance abuse, and

were somatically healthy. They were thoroughly checked for psychiatric morbidity using the Structured Clinical Interviews for DSM Disorders (SCID I and II). All controls were free of

medication. Our study was carried out in accordance with ‘The code of ethics of the world medical association (Declaration of Helsinki)’ for experiments including humans:

http://www.wma.net/e/policy/b3.htm. The Regional Ethical Review Boards in Lund, Linköping and Malmö approved the study. After complete description of the study to the subjects, written

informed consent was obtained. PHYSICAL EXAMINATION AND LUMBAR PUNCTURES All patients and controls underwent a general physical examination. The BMI for patients and controls were 23.7±3.5

(mean±s.d.) and 24.2±3.9, respectively. In all, 31% of the patients used nicotine _vs_ 19.4% of the controls. In order to identify subjects with potential infections at the time of the

lumbar punctures, we analyzed blood samples for white blood cell count, erythrocyte sedimentation rate or C-reactive protein, and the subjects were checked for fever. No evidence of ongoing

clinical infection was found, as defined by the normal reference intervals of these parameters. A complete medical history was taken. Somatic diagnoses of the patients are shown in Table 1.

We performed lumbar punctures in the morning between 0800 and 0900hours, after a night of fasting and bed rest. CSF was collected from the L4–L5 interspace using a standardized protocol, and

immediately stored at −80 °C. PSYCHIATRIC DIAGNOSTICS AND RATING SCALES Briefly after the suicide attempt, a psychiatrist diagnosed the patients according to the Diagnostic and Statistical

Manual of Mental Disorders (DSM)-IIIR Axis I and II Disorders (American Psychiatric Association, 1987). The diagnoses were set after a ∼2-hour long structured interview using the

Comprehensive Psychiatric Rating Scale and the Structured Clinical Interview for DSM Disorders (SCID I and II). The patients were also evaluated by means of the Suicide Intent Scale,

measuring the determination to commit suicide (Beck, 1974). The scale is subdivided in two parts, dealing with objective (active preparation) and subjective circumstances related to the

attempt. Some, but not all studies also find an association between high scores on the scale and future completed suicide (Freedenthal, 2008; Stefansson et al, 2012). In all, 53 out of 64

patients completed the Suicide Intent Scale. Moreover, we evaluated depressive symptoms using the Montgomery–Asberg Depression Rating Scale (MADRS), which is a 10-item scale with a maximum

score of 60 (Montgomery and Asberg, 1979). In all, 60 out of 64 patients completed the MADRS rating. DEFINITION OF SUICIDE ATTEMPTS A suicide attempt was defined as ‘situations in which a

person has performed an actually or seemingly life-threatening behavior with the intent of jeopardizing his/her life or to give the appearance of such intent, but which has not resulted in

death’ (Beck et al, 1973). The intent to commit suicide was explicit upon interview. Patients who did not state a clear intent were not enrolled. Suicide attempts were classified into

violent and nonviolent acts as defined (Traskman et al, 1981). Drug overdoses by ingestion, single wrist-cuts or a combination are considered nonviolent suicide attempts, whereas all other

methods (for example, hanging, drowning, gas poisoning, several deep cuts) are classified as violent. PARTICIPANTS, FOLLOW-UP STUDY A subset of the patients that were originally enrolled in

the study at the suicide attempt participated in a follow-up study. The patients returned to the clinic and contributed with CSF samples at repeated occasions after the suicide attempt.

Paired samples from eight patients, three male and five female individuals, were available from the index (the suicide attempts) and a time-point within 6 months after the attempt. Mean age

of these patients was 38 years, range 22–51 years. Five of the patients received antidepressant medication at the follow-up occasion and one patient received disulfiram. BIOLOGICAL ASSAYS

ANALYSIS OF QUIN QUIN was analyzed by gas chromatography mass spectrometry as previously described (Smythe et al, 2002). The internal standard, [2H3]QUIN (99%) was purchased from Le Research

Inc. (St Paul, MN, USA). Trifluoroacetic anhydride and 1,1,1,3,3,3-hexafluoro-2-propanol of GC derivatization grade, QUIN and other organic solvents of analytical-grade were all obtained

from Sigma-Aldrich (St Louis, MO, USA). We injected 1 μl of sample into an Agilent 6890 gas chromatograph, interfaced to an Agilent 5973 mass selective detector via an auto-sampler Agilent

Technologies 7683 operating in negative ionization mode, and controlled using Agilent ChemStation software (Agilent, Santa Clara, CA, USA). Inter- and intra-assay precision is consistently

5–8%. ANALYSIS OF KYNA KYNA was analyzed as previously described (Olsson et al, 2010) utilizing an isocratic reversed-phase high-performance liquid chromatography system, including a dual

piston, high liquid delivery pump (Bischoff, Leonberg, Germany), a ReproSil-Pur C18 column (silica pore size, 3μm (4 × 100 mm, Dr Maisch GmbH, Ammerbuch, Germany) and a fluorescence detector

(Jasco Ltd, Hachioji City, Japan) with an excitation wavelength of 344 nm and an emission wavelength of 398 nm (18 nm bandwidth). A mobile phase of 50 mM sodium acetate (pH 6.2, adjusted

with acetic acid) and 7.0% acetonitrile was pumped through the reversed-phase column at a flow rate of 0.5 ml/min. 50 μl samples were manually injected (ECOM, Prague, Czech Republic). 0.5 M

zinc acetate (not pH adjusted) was delivered post-column by a peristaltic pump (_P_-500, Pharmacia, Uppsala, Sweden) at a flow rate of 0.10 ml/min. The signals from the fluorescence detector

were transferred to a computer for analysis with Datalys Azur (Grenoble, France). Retention time of KYNA was 7–8 min. Standard concentrations were used to relate the height of the peaks in

the chromatogram to the correct concentration of KYNA in the samples. Inter- and intra-assay precision is consistently 3–8%. For KYNA analysis, CSF was available from 60 patients and 37

controls. ANALYSIS OF IL-6 We analyzed IL-6 in CSF using high-sensitivity electrochemiluminescence (MesoScale Discovery, Gaithersburg, Maryland, USA) as per the manufacturer’s protocol. CSF

samples were analyzed in duplicates on a SECTOR 6000 instrument (www.mesoscale.com). The detection limit was 0.1 pg/ml. The absolute IL-6 measures have been published elsewhere (Lindqvist et

al, 2009). Here, the correlation with QUIN was analyzed. For the correlation analyses, IL-6 measures from 63 patients and 24 controls were available. STATISTICAL ANALYSIS AND POTENTIAL

CONFOUNDERS The Statistical Package for the Social Sciences (SPSS) program version 18.00 for Windows was used (IBM Corporation, New York, NY, USA). CSF levels of IL-6 and QUIN displayed

skewness >2, and the values were transformed into normal distribution using the natural logarithms for statistical analysis. The potential impacts of age, gender, weight, BMI, smoking and

length of wash-out period on QUIN and KYNA levels were investigated with Student’s _t_-tests and Pearson correlations. To correct for age, linear regression models were used with QUIN as

dependent variable and age as independent variable. Student’s _t_-tests were used for comparisons of KYNA and age-corrected QUIN between independent groups. As KYNA and QUIN have opposing

effects on the NMDA receptor, the ratio between CSF QUIN (age-corrected) and CSF KYNA (CSF QUIN/CSF KYNA) was calculated and the ratio was compared between suicide attempters and controls

with Student’s _t_-tests. In addition, linear regression analyses were conducted to determine the effect of sample storage time: QUIN or KYNA were entered as dependent variable, whereas

group (patients _vs_ controls), age and sample storage time as independent variables. Age-corrected QUIN was compared between healthy controls, suicide attempters with a diagnosis of a

primary mood disorder (major depressive disorder and depression NOS) and suicide attempters with other diagnoses using one-way ANOVA followed by Bonferroni–Dunn’s _post-hoc_ test.

Age-corrected QUIN was also compared between the control group and five main diagnostic groups (Major Depressive Disorder, Dysthymia, Adjustment Disorder, Substance Abuse, Depression NOS)

using one-way ANOVA. Finally, the impact of personality disorder, type of suicide attempt and wash-out on age-corrected QUIN were determined using one-way ANOVAs. Spearman’s _ρ_ was used for

correlation analysis of age-corrected QUIN and scores on the Suicide Intent Scale, as well as MADRS. Paired _t_-tests were used for QUIN, KYNA and MADRS measures within the same individuals

in the follow-up study. _α_-level of significance was set at _P_=0.05. RESULTS CSF LEVELS OF QUIN AND KYNA We found that CSF QUIN was significantly higher in suicide attempters (41.9±4 nM;

mean±s.e.m.; _n_=64) than in healthy controls (18.2±0.8 nM; _n_=36) (Student’s _t_-test, _t_=−5.39, df=93.88, _P_<0.001) (Figure 2a). In contrast, there was no significant difference in

the levels of CSF KYNA between suicide attempters and healthy controls (Student’s _t_-test, _t_=0.429, df=93.70, _P_=0.67) (Figure 2b). The concentrations of the respective metabolites are

shown in Table 2. As KYNA and QUIN have opposing effects on the NMDA receptor, we investigated the CSF QUIN/CSF KYNA ratio. We found that this ratio was significantly larger in the suicidal

patients than in the healthy controls (Student’s _t_-test, _t_=−3.72, df=74.41, _P_<0.001) (Figure 2c). There was also a significant positive correlation between the cytokine IL-6 in CSF

and QUIN (_n_=87, Pearson’s _R_=0.23, _P_=0.033) (Figure 3a). DEMOGRAPHICS AND POTENTIAL CONFOUNDERS We investigated the potential impact of age, gender, weight, BMI, smoking, storage-time

and length of wash-out period on QUIN and KYNA levels. QUIN showed a slight but significant increase with age of the subjects (_n_=100, Pearson’s _R_=0.21, _P_=0.038) (Figure 3b). We

therefore used age-corrected variables for all statistical analyses except the within-subject analysis in the follow-up study (section 3.4). Age of the subjects did not correlate with KYNA

(_n_=97, Pearson’s _R_=0.043, _P_=0.68) (Figure 3c). There was no impact of gender, smoking, weight, BMI or wash-out length on QUIN nor KYNA (_t_-tests and Pearson correlations, _P_>0.1

for all variables). As the patient samples had been stored for a long time in our biobank, we also conducted a linear regression analyses to see if storage time had affected the levels of

QUIN and KYNA. The model was still highly significant; _β_=0.81, _P_=0.001 for suicidality (patients _vs_ controls). There was a trend for a storage dependent decline of CSF QUIN; _β_=−0.41,

_P_=0.075 for storage-time (Figure 3d). Thus, the QUIN levels in the samples from the suicide attempters in the biobank were potentially even higher initially. There was no effect of

storage-time on CSF-KYNA (linear regression, _P_>0.1). Both patients who were unmedicated at the suicide attempt (_n_=6) and those who went through the wash-out (_n_=58) had significantly

elevated QUIN levels compared with the controls (one-way ANOVA (F(2,97)=11.15, _P_<0.001; followed by Bonferroni–Dunn’s _post-hoc_ tests, _P_=0.003 for unmedicated _vs_ controls;

_P_<0.001 for washed-out _vs_ controls; NS for washed-out _vs_ unmedicated) (Table 2). QUIN, SUICIDALITY AND DEPRESSIVE SYMPTOMS The mean score on the SIS was 18.3±0.8 (±s.e.m.). We found

that QUIN measures in CSF correlated positively with the total score on the Suicide Intent Scale (_n_=53, Spearman _ρ_=0.30, _P_=0.028) (Figure 3e). The most robust correlation was between

QUIN and the subscale concerning objective circumstances in conjunction with the suicide attempt (_n_=53, Spearman _ρ_=0.34, _P_=0.012) (Figure 3f). The definition of the objective

circumstances can be found in section 2.3. CSF samples from suicide attempters were furthermore divided with regards to the use of violent (_n_=16) or nonviolent (_n_=48) methods for the

attempts, as defined in the ‘Materials and Methods’ section. QUIN levels differed significantly between control subject, violent suicide attempters and nonviolent suicide attempters (one-way

ANOVA (F(2,97)=13.16, _P_<0.001). There was a trend for higher levels of CSF QUIN in patients who had made violent suicide attempts than the patients who had made nonviolent suicide

attempts (Bonferroni–Dunn’s _post-hoc_ test, _P_=0.059) (Figure 2d and Table 2). Both violent and nonviolent attempter groups showed higher QUIN compared with the control group

(Bonferroni–Dunn’s _post-hoc_ test, _P_<0.001 for violent attempters _vs_ controls and _P_=0.002 for nonviolent attempters _vs_ controls). The mean score on the MADRS was 16.3±1.4

(±s.e.m.). We found no significant correlation between QUIN and the MADRS scores (_n_=60, Spearman _ρ_=0.006, _P_=0.97). There was no correlation between QUIN and MADRS suicidality item

(_n_=60, Spearman _ρ_=0.072, _P_=0.59). QUIN IN DIAGNOSTIC SUBGROUPS We compared the QUIN levels in suicide attempters with a diagnosis of a primary mood disorder (Major Depressive Disorder

and Depression NOS) (_n_=31) with suicide attempters with other diagnoses (_n_=33) and controls. A one-way ANOVA showed significant differences between the groups (_F_(2,97)=9.81,

_P_<0.001). _Post-hoc_ testing showed that there was no significant difference in mean QUIN levels between suicide attempters with and without a mood disorder (NS), whereas both groups

differed significantly _vs_ the healthy controls (_P_=0.001 for primary mood disorder _vs_ controls; _P_<0.001 other diagnoses _vs_ controls; Bonferroni–Dunn’s _post-hoc_ tests) (Figure

2e and Table 2). We also found significant differences in QUIN levels when comparing control group and the five main diagnostic groups of suicide attempters including Major Depressive

Disorder, _n_=22; Adjustment Disorder, _n_=11; Depression NOS, _n_=9; Substance Abuse, _n_=6 and Dysthymia, _n_=4 (one-way ANOVA, (F(5,82)=4.64, _P_=0.001). _Post-hoc_ testing showed that

QUIN levels were not different between the five main diagnostic groups (Bonferroni–Dunn’s _post-hoc_ test, _p_>0.1 for all comparisons). QUIN levels did not differ between suicide

attempters with (_n_=38) and without (_n_=22) personality disorder, but was higher in both groups compared with controls (one-way ANOVA (F(2,93)=11.42, _P_<0.001; followed by

Bonferroni–Dunn’s _post-hoc_ test, _P_>0.1 for personality disorder _vs_ no personality disorder; _P_<0.001 for personality disorder _vs_ controls and _P_<0.001 for no personality

disorder _vs_ controls) (Table 2). QUIN LEVELS 6 MONTHS AFTER THE SUICIDE ATTEMPT (FOLLOW-UP) The CSF QUIN levels decreased significantly from the time of the suicide attempt to the

follow-up occasion, from 41.6±12.4 nM to 16.2±4.5 nM (mean±s.e.m.) (paired samples _t_-test, _t_=2.39, df=7, _P_<0.05) (Figure 2f). Thus, CSF QUIN in the patients at follow-up had

normalized to that of controls. There was no significant change in CSF KYNA, which decreased from 1.3±0.3 nM to 1.2±0.3 nM (mean±s.e.m.) (paired samples _t_-test, _t_=0.37, df=7, _P_=0.72).

There was a trend for a decrease in MADRS scores, from 16.8±2.0 (mean±s.e.m.) at the suicide attempt to 10.0±4.3 (mean±s.e.m.) at the follow-up occasion, in these eight patients (paired

samples _t_-test, _t_=2.0, df=7, _P_=0.09). DISCUSSION We found significantly increased levels of the NMDA-receptor agonist QUIN in the CSF of suicide attempters. In line with previous

studies showing that inflammation can trigger generation of QUIN (Achim et al, 1993; Heyes et al, 1995), there was a significant correlation between CSF levels of QUIN and the

pro-inflammatory cytokine IL-6. In contrast, levels of the NMDA-receptor antagonist KYNA were not elevated. This suggests that an overall agonistic effect on the NMDA-receptors is present in

suicide attempters. Moreover, this finding provides a neurobiological rationale for the recent reports describing that ketamine, by blocking NMDA-receptor transmission, can alleviate

symptoms of suicidality (DiazGranados et al, 2010b; Larkin and Beautrais, 2011; Price et al, 2009; Zarate et al, 2012). In our patients, the raised QUIN levels were also significantly

associated with the degree of suicidal intent, further strengthening the association between QUIN and suicidality. KYNA, which is mainly synthesized in astrocytes, blocks NMDA receptors and

has neuroprotective and anticonvulsive properties (Erhardt et al, 2009; Schwarcz et al, 2012). In contrast, QUIN, which is produced by activated microglia, is a potent excitotoxin with

neurotoxic, gliotoxic and pro-inflammatory properties (Guillemin, 2012; Schwarcz et al, 2012). Increased levels of QUIN might therefore potentially contribute to the neuronal loss and to the

reduced hippocampal volume observed in patients with major depression (Bremner et al, 2000; McKinnon et al, 2009). Moreover, increased extracellular levels of QUIN, as reflected by

increased CSF concentrations in suicide attempters, are likely to facilitate glutamate neurotransmission prior to causing apoptosis. In addition to being a direct NMDA receptor agonist, QUIN

increases neuronal glutamate release as well as decreases glutamate uptake and recycling by astrocytes (Guillemin, 2012). Effects on the glutamate system have been suggested to contribute

to the pathogenesis in patients with severe mood disorders (Hashimoto, 2009; Sanacora et al, 2008; Schwarcz et al, 2012). There has been no evidence of increased CSF QUIN in patients with

primary depressive disorders or suicidality until now. In line with our findings, Steiner et al, (2011) recently observed increased QUIN-immunoreactivity in microglia in the anterior

cingulate gyrus _post-mortem_ of suicide victims that suffered from severe depression. Interestingly, the increase in CSF QUIN observed in our current study was not related to the severity

of depressive symptoms. In agreement with this, QUIN levels were increased in all suicide attempters, regardless if they had a diagnosis of a mood disorder or not. Therefore, our study may

suggest that elevated QUIN is specifically linked to suicidality rather than to the severity of depression. However, no non-suicide attempters with depressive symptoms were included in our

study. Therefore, inflammation and subsequent stimulation of glutamate neurotransmission could potentially be prevalent in so-called treatment-resistant or severe depression; diagnostic

groups where suicides, attempts and suicidal ideation all are common (Brent et al, 2009; Price et al, 2009; Steiner et al, 2011). There are several studies showing an effect of ketamine on

patients with treatment-resistant depression, where suicidality has not specifically been an outcome measure (Diazgranados et al, 2010a; Ibrahim et al, 2012; Murrough et al, 2012). Further

studies evaluating CSF QUIN in diagnostic subgroups should be undertaken in order to develop tailor-made treatments in the future. It should be pointed out that we did not study any causal

relation between biological factors and symptoms. This study analyzes associations and significant changes in primary psychiatric patients and controls. Important studies showing a causal

relation between inflammatory factors and depressive symptoms have previously been performed in patients with hepatitis C, and demonstrated that peripheral injection with interferon-_α_

increased CSF levels of QUIN, KYNA and pro-inflammatory cytokines along with depressive symptoms (Raison et al, 2010; Raison et al, 2009). In addition to the elevation in QUIN at the suicide

attempt, we here also found a decrease of CSF QUIN in the eight patients who returned for a follow-up lumbar puncture within 6 months of the attempt. At this time-point, there was also a

trend towards decreased depressive symptoms. However, the follow-up study sample was small, and the patients had initiated different types of medications. It is thus not possible to draw any

conclusions about what caused the decrease in QUIN at the follow-up occasion, or whether this was related to a decrease in depressive symptoms and/or suicidality. Analysis of long-term

variation of symptoms and biological factors in large numbers of psychiatric patients is highly warranted in the future. Our study supports the hypothesis that a low-grade CNS inflammation

induces production of QUIN, which has effects on glutamate neurotransmission and might lead to symptoms of suicidality. The positive correlation between the cytokine IL-6 and QUIN in suicide

attempters is in line with findings in patients suffering from CNS infections, where both CSF IL-6 and QUIN are elevated (Heyes et al, 1995). Studies showing immunohistochemical evidence of

microgliosis and an increased density of QUIN-immunoreactive microglial cells in suicide victims further support that brain inflammation, increased QUIN levels and suicide are linked

(Steiner et al, 2008; Steiner et al, 2011). As an additional mechanism, reduced activity of the enzyme downstream of QUIN production, quinolinate phosphoribosyl-transferase, could

potentially lead to an accumulation of QUIN. The enzyme degrades QUIN into nicotinic acid ribonucleotide and causes subsequent NAD+ formation (Figure 1). It is also possible that peripheral

inflammation may contribute to the synthesis of brain QUIN and KYNA. Plasma levels of kynurenine (precursor of QUIN and KYNA) are elevated in patients with major depressive disorder and a

history of suicide attempts (Sublette et al, 2011). Kynurenine can pass the blood brain barrier and subsequently be metabolized into QUIN and KYNA by microglia and astrocytes. However, QUIN

and KYNA themselves do _not_ pass the blood-brain barrier and therefore CSF samples are needed to study the levels of these neuroactive metabolites in the CNS compartment (Schwarcz et al,

2012). An intriguing question is why QUIN is accumulating in excess over KYNA in suicide attempters, as both metabolites are generated in states of inflammation. In this respect, the

regulation of enzymes in the kynurenine pathway deserves further investigation and could potentially depend on genetic variants (Claes et al, 2011). An imbalance in the activity of enzymes

along the kynurenine pathway might explain why QUIN accumulates, or is produced in preference over KYNA in suicidal patients. Considering that inflammation and dysregulation of glutamate

neurotransmission might contribute to the pathophysiology of suicidal behavior, we propose that novel treatments of suicidality should be directed against these systems. Clinical trials

using cyclo-oxygenase-2 inhibitors as add-on therapy in patients with treatment-resistant depression are promising (Akhondzadeh et al, 2009; Muller et al, 2006). Novel therapeutic strategies

include inhibition of the enzyme IDO-1 or microglial activation (in order to reduce synthesis of QUIN), specific cytokine blockers or direct blockade of the NMDA-receptor (Haroon et al,

2012). These treatments could be tested in future trials enrolling patients based on suicidality. As mentioned above, the NMDA receptor antagonist ketamine was effective in initial trials

treating suicidal symptoms. Moreover, the primary trigger of the elevated immune parameters in suicidality is currently unknown and once unraveled, it might constitute another drug target.

In this context, it is of importance to keep in mind that suicidality is likely to be a complex phenomenon, not depending on a single cause. So-called distal risk factors include genetic

loading, trait impulsivity and early traumatic life events, whereas proximal risk factors include psychological crisis or acute stress (Mann and Currier 2010); Gradus et al, 2010; Hawton and

van Heerningen, 2009). It has been demonstrated that pro-inflammatory cytokines IL-6 and IL-1_β_ increase after acute stress (Steptoe et al, 2007). Psychological factors could thus

potentially trigger a cascade of reactions ultimately leading to increased QUIN production. Another factor that recently has been associated with suicidality is the neurotrophic parasite _T.

gondii_ (Pedersen et al, 2012; Zhang et al, 2012). The parasite has been suggested to increase dopamine production as well as induce low-grade inflammation. These examples show that in

order to achieve optimal symptom relief for suicidal patients, it would most likely be vital to identify and treat triggers of inflammation, as well as acute symptoms. In summary, this is to

our knowledge the first report of elevated QUIN, an endogenous NMDA agonist of microglial origin, in the CSF of suicide attempters. CSF QUIN was associated with the degree of suicidal

intent and when a subgroup of patients came back for a follow-up visit, CSF QUIN levels had returned to normal. These findings suggest that increased CSF QUIN is specifically related to the

pathophysiology of suicidality. As QUIN is an NMDA receptor agonist, our findings may provide a scientific rationale for the reduced suicidal ideation by the NMDA-receptor antagonist

ketamine. Given that suicidal behavior is a major public health problem worldwide, with a poorly understood pathophysiology, our findings may lead to the development of novel tools to

diagnose, follow and treat this source of morbidity and mortality across diagnostic boundaries. REFERENCES * Achim CL, Heyes MP, Wiley CA (1993). Quantitation of human immunodeficiency

virus, immune activation factors, and quinolinic acid in AIDS brains. _J Clin Invest_ 91: 2769–2775. Article  CAS  PubMed  PubMed Central  Google Scholar  * Akhondzadeh S, Jafari S, Raisi F,

Nasehi AA, Ghoreishi A, Salehi B _et al_ (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. _Depress

Anxiety_ 26: 607–611. Article  CAS  PubMed  Google Scholar  * American Psychiatric Association (1987) _Diagnostic and Statistical Manual of Mental Disorders_. American Psychiatric Press:

Washington, DC. * Asberg M, Traskman L (1981). Studies of CSF 5-HIAA in depression and suicidal behaviour. _Adv Exp Med Biol_ 133: 739–752. Article  CAS  PubMed  Google Scholar  * Beck AT

(1974) _The Prediction of Suicide_. Charles Press: Bowie, Md. Google Scholar  * Beck AT, Davis JH, Frederick CJ, Perlin S, Pokorny AD, Schulman RE (1973). Classification and nomenclature.

In: Resnik HLP, Hathorne BC (eds) _Suicide Prevention in the Seventies_. US Government Printing Office: Washington DC. pp 7–12. Google Scholar  * Bremner JD, Narayan M, Anderson ER, Staib

LH, Miller HL, Charney DS (2000). Hippocampal volume reduction in major depression. _Am J Psychiatry_ 157: 115–118. Article  CAS  PubMed  Google Scholar  * Brent DA, Emslie GJ, Clarke GN,

Asarnow J, Spirito A, Ritz L _et al_ (2009). Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents

(TORDIA) study. _Am J Psychiatry_ 166: 418–426. Article  PubMed  PubMed Central  Google Scholar  * Bruffaerts R, Demyttenaere K, Hwang I, Chiu WT, Sampson N, Kessler RC _et al_ (2011).

Treatment of suicidal people around the world. _Br J Psychiatry_ 199: 64–70. Article  PubMed  PubMed Central  Google Scholar  * Claes S, Myint AM, Domschke K, Del-Favero J, Entrich K,

Engelborghs S _et al_ (2011). The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. _Psychiatry Res_ 188: 355–360. Article  CAS  PubMed

  Google Scholar  * Da Cruz D, Pearson A, Saini P, Miles C, While D, Swinson N _et al_ (2011). Emergency department contact prior to suicide in mental health patients. _Emerg Med J_ 28:

467–471. Article  CAS  PubMed  Google Scholar  * de Carvalho LP, Bochet P, Rossier J (1996). The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate

between NMDAR2 receptor subunits. _Neurochem Int_ 28: 445–452. Article  CAS  PubMed  Google Scholar  * Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S _et al_

(2010a). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. _Arch Gen Psychiatry_ 67: 793–802. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA _et al_ (2010b). Rapid resolution of suicidal ideation after a single infusion of an

N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. _J Clin Psychiatry_ 71: 1605–1611. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Duman RS, Aghajanian GK (2012). Synaptic dysfunction in depression: potential therapeutic targets. _Science_ 338: 68–72. Article  CAS  PubMed  PubMed Central  Google Scholar  * Erhardt S,

Olsson SK, Engberg G (2009). Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. _CNS Drugs_ 23: 91–101. Article  CAS  PubMed  Google Scholar

  * Ernst C, Mechawar N, Turecki G (2009). Suicide neurobiology. _Prog Neurobiol_ 89: 315–333. Article  CAS  PubMed  Google Scholar  * Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC,

Gomes S _et al_ (2010). Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. _Clin Neuropharmacol_ 33: 312–316. Article 

CAS  PubMed  Google Scholar  * Freedenthal S (2008). Assessing the wish to die: a 30-year review of the suicide intent scale. _Arch Suicide Res_ 12: 277–298. Article  PubMed  Google Scholar

  * Gradus JL, Qin P, Lincoln AK, Miller M, Lawler E, Sorensen HT _et al_ (2010). Acute stress reaction and completed suicide. _Int J Epidemiol_ 39: 1478–1484. Article  PubMed  Google

Scholar  * Guillemin GJ (2012). Quinolinic acid, the inescapable neurotoxin. _FEBS J_ 279: 1356–1365. Article  CAS  PubMed  Google Scholar  * Haroon E, Raison CL, Miller AH (2012).

Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. _Neuropsychopharmacology_ 37: 137–162. Article  CAS  PubMed  Google

Scholar  * Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. _Brain Res Rev_ 61: 105–123. Article  CAS  PubMed  Google Scholar  * Hawton K,

van Heeringen K (2009). Suicide. _Lancet_ 373: 1372–1381. Article  PubMed  Google Scholar  * Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M _et al_ (1992). Quinolinic acid and

kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. _Brain_ 115 (Pt 5): 1249–1273. Article  PubMed  Google Scholar  * Heyes MP, Saito K, Milstien S,

Schiff SJ (1995). Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children. _J Neurol Sci_ 133: 112–118. Article  CAS  PubMed  Google Scholar

  * Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases

non-alpha7 nicotinic receptor expression: physiopathological implications. _J Neurosci_ 21: 7463–7473. Article  CAS  PubMed  PubMed Central  Google Scholar  * Ibrahim L, Diazgranados N,

Franco-Chaves J, Brutsche N, Henter ID, Kronstein P _et al_ (2012). Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from

a 4-week, double-blind, placebo-controlled study. _Neuropsychopharmacology_ 37: 1526–1533. Article  CAS  PubMed  PubMed Central  Google Scholar  * Janelidze S, Mattei D, Westrin A,

Traskman-Bendz L, Brundin L (2011). Cytokine levels in the blood may distinguish suicide attempters from depressed patients. _Brain Behav Immun_ 25: 335–339. Article  CAS  PubMed  Google

Scholar  * Larkin GL, Beautrais AL (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. _Int J Neuropsychopharmacol_

14: 1127–1131. Article  CAS  PubMed  Google Scholar  * Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L _et al_ (2009). Interleukin-6 is elevated in the cerebrospinal

fluid of suicide attempters and related to symptom severity. _Biol Psychiatry_ 66: 287–292. Article  CAS  PubMed  Google Scholar  * Mann JJ, Currier DM (2010). Stress, genetics and

epigenetic effects on the neurobiology of suicidal behavior and depression. _Eur Psychiatry_ 25: 268–271. Article  CAS  PubMed  Google Scholar  * McKinnon MC, Yucel K, Nazarov A, MacQueen GM

(2009). A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. _J Psychiatry Neurosci_ 34: 41–54. PubMed  PubMed Central  Google

Scholar  * Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. _Br J Psychiatry_ 134: 382–389. Article  CAS  PubMed  Google Scholar  * Muller N,

Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B _et al_ (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a

double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. _Mol Psychiatry_ 11: 680–684. Article  CAS  PubMed  Google Scholar  * Murrough JW, Perez AM, Pillemer S, Stern

J, Parides MK, Aan Het Rot M _et al_ (2012). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. _Biol Psychiatry_ e-pub

ahead of print 26 July 2012. doi: 10.1016/j.biopsych.2012.06.02. * Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S (2008). Suicide and suicidal behavior. _Epidemiol Rev_ 30: 133–154.

Article  PubMed  Google Scholar  * Olsson SK, Samuelsson M, Saetre P, Lindstrom L, Jonsson EG, Nordin C _et al_ (2010). Elevated levels of kynurenic acid in the cerebrospinal fluid of

patients with bipolar disorder. _J Psychiatry Neurosci_ 35: 195–199. Article  PubMed  PubMed Central  Google Scholar  * Oxenkrug GF (2010). Tryptophan kynurenine metabolism as a common

mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. _Isr J Psychiatry Relat Sci_ 47: 56–63. PubMed  PubMed Central

  Google Scholar  * Pedersen MG, Mortensen PB, Norgaard-Pedersen B, Postolache TT (2012). _Toxoplasma_ _gondii_ infection and self-directed violence in mothers. _Arch Gen Psychiatry_ 69:

1123–1130. Article  PubMed  Google Scholar  * Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in

treatment-resistant depression. _Biol Psychiatry_ 66: 522–526. Article  CAS  PubMed  PubMed Central  Google Scholar  * Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ _et

al_ (2009). Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. _Biol Psychiatry_ 65: 296–303. Article  CAS  PubMed 

Google Scholar  * Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G _et al_ (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with

IFN-alpha: relationship to CNS immune responses and depression. _Mol Psychiatry_ 15: 393–403. Article  CAS  PubMed  Google Scholar  * Sanacora G, Zarate CA, Krystal JH, Manji HK (2008).

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. _Nat Rev Drug Discov_ 7: 426–437. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012). Kynurenines in the mammalian brain: when physiology meets pathology. _Nat Rev Neurosci_ 13: 465–477. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Sher L (2011). Brain-derived neurotrophic factor and suicidal behavior. _QJM_ 104: 455–458. Article  CAS  PubMed  Google Scholar  * Smythe GA, Braga O, Brew BJ, Grant RS,

Guillemin GJ, Kerr SJ _et al_ (2002). Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. _Anal

Biochem_ 301: 21–26. Article  CAS  PubMed  Google Scholar  * Stefansson J, Nordstrom P, Jokinen J (2012). Suicide Intent Scale in the prediction of suicide. _J Affect Disord_ 136: 167–171.

Article  CAS  PubMed  Google Scholar  * Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C _et al_ (2008). Immunological aspects in the neurobiology of suicide: elevated microglial

density in schizophrenia and depression is associated with suicide. _J Psychiatr Res_ 42: 151–157. Article  PubMed  Google Scholar  * Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG,

Sarnyai Z _et al_ (2011). Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated

glutamatergic neurotransmission? _J Neuroinflammation_ 8: 94. Article  CAS  PubMed  PubMed Central  Google Scholar  * Steptoe A, Hamer M, Chida Y (2007). The effects of acute psychological

stress on circulating inflammatory factors in humans: a review and meta-analysis. _Brain Behav Immun_ 21: 901–912. Article  CAS  PubMed  Google Scholar  * Stone TW (1993). Neuropharmacology

of quinolinic and kynurenic acids. _Pharmacol Rev_ 45: 309–379. CAS  PubMed  Google Scholar  * Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA _et al_ (2011). Plasma

kynurenine levels are elevated in suicide attempters with major depressive disorder. _Brain Behav Immun_ 25: 1272–1278. Article  CAS  PubMed  PubMed Central  Google Scholar  * Traskman L,

Asberg M, Bertilsson L, Sjostrand L (1981). Monoamine metabolites in CSF and suicidal behavior. _Arch Gen Psychiatry_ 38: 631–636. Article  CAS  PubMed  Google Scholar  * Wichers MC, Koek

GH, Robaeys G, Verkerk R, Scharpe S, Maes M (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. _Mol Psychiatry_

10: 538–544. Article  CAS  PubMed  Google Scholar  * Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A _et al_ (2012). Replication of ketamine's

antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. _Biol Psychiatry_ 71: 939–946. Article  CAS  PubMed  PubMed Central  Google Scholar  * Zhang Y,

Traskman-Bendz L, Janelidze S, Langenberg P, Saleh A, Constantine N _et al_ (2012). _Toxoplasma gondii_ immunoglobulin G antibodies and nonfatal suicidal self-directed violence. _J Clin

Psychiatry_ 73: 1069–1076. Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS This study was supported by the Swedish Research Council Grants No. 2009-4284 and

2011-4787 (Lena Brundin), 2002-5297 and 2008-2922 (Lil Träskman-Bendz), and 2009-7052 and 2011-4795 (Sophie Erhardt), the Province of Scania clinical state grants (ALF, for Lena Brundin and

Lil Träskman-Bendz), the American Foundation for Suicide Prevention 2-DIG-00030-0608-1208 (Teodor Postolache), the Rebecca Cooper Foundation (Gilles Guillemin) and the National Health

Medical Research Council in Australia (NHMRC) (Gilles Guillemin). AUTHOR INFORMATION Author notes * Gilles J Guillemin and Lena Brundin: Shared senior authorship. AUTHORS AND AFFILIATIONS *

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden Sophie Erhardt & Klas R Linderholm * Department of Pharmacology, School of Medical Sciences,

University of New South Wales, Sydney, NSW, Australia Chai K Lim & Gilles J Guillemin * Department of Clinical Sciences, Section of Psychiatry, Psychoimmunology Unit, Lund University,

Lund, Sweden Shorena Janelidze, Daniel Lindqvist, Lil Träskman-Bendz & Lena Brundin * Department of Clinical and Experimental Medicine, Division of Psychiatry, Faculty of Health

Sciences, Linköping University, Linköping, Sweden Martin Samuelsson & Kristina Lundberg * Mood and Anxiety Program, University of Maryland School of Medicine and the VA Capitol

Healthcare Network (VISN 5) Mental Illness Research, Education and Clinical Center, Baltimore, MD, USA Teodor T Postolache * Australian School of Advanced Medicine (ASAM), Macquarie

University, NSW, Australia Gilles J Guillemin * Department of Translational Science and Molecular Medicine, Michigan State University, Van Andel Research Institute, Grand Rapids, MI, USA

Lena Brundin Authors * Sophie Erhardt View author publications You can also search for this author inPubMed Google Scholar * Chai K Lim View author publications You can also search for this

author inPubMed Google Scholar * Klas R Linderholm View author publications You can also search for this author inPubMed Google Scholar * Shorena Janelidze View author publications You can

also search for this author inPubMed Google Scholar * Daniel Lindqvist View author publications You can also search for this author inPubMed Google Scholar * Martin Samuelsson View author

publications You can also search for this author inPubMed Google Scholar * Kristina Lundberg View author publications You can also search for this author inPubMed Google Scholar * Teodor T

Postolache View author publications You can also search for this author inPubMed Google Scholar * Lil Träskman-Bendz View author publications You can also search for this author inPubMed 

Google Scholar * Gilles J Guillemin View author publications You can also search for this author inPubMed Google Scholar * Lena Brundin View author publications You can also search for this

author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Lena Brundin. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare that, except for income received from the

primary employers, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service; and there

are no personal financial holdings that could be perceived as constituting a potential conflict of interest. None of the funding organizations listed above had any role in the design or

conduct of the study, the data analysis, in the preparation of the manuscript or in the decision to submit the work for publication. ADDITIONAL INFORMATION Supplementary Information

accompanies the paper on the Neuropsychopharmacology website SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 (DOC 60 KB) POWERPOINT SLIDES POWERPOINT SLIDE FOR FIG. 1 POWERPOINT SLIDE FOR

FIG. 2 POWERPOINT SLIDE FOR FIG. 3 RIGHTS AND PERMISSIONS This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy

of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Erhardt, S., Lim, C., Linderholm, K. _et al._

Connecting inflammation with glutamate agonism in suicidality. _Neuropsychopharmacol_ 38, 743–752 (2013). https://doi.org/10.1038/npp.2012.248 Download citation * Received: 22 August 2012 *

Revised: 02 November 2012 * Accepted: 26 November 2012 * Published: 03 December 2012 * Issue Date: April 2013 * DOI: https://doi.org/10.1038/npp.2012.248 SHARE THIS ARTICLE Anyone you share

the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * quinolinic acid * suicide * depression * glutamate * cytokine